

Jennifer L Whitwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/916064/publications.pdf>

Version: 2024-02-01

246
papers

20,384
citations

16411

64
h-index

11899

134
g-index

268
all docs

268
docs citations

268
times ranked

15330
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>APOEϵ4</i> influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 784-796.	0.4	7
2	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 441-451.	1.2	1
3	Relationship Between ¹⁸ F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies. <i>Journal of Nuclear Medicine</i> , 2022, 63, 931-935.	2.8	9
4	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. <i>Movement Disorders</i> , 2022, 37, 213-218.	2.2	6
5	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 491-498.	1.2	8
6	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. <i>NeuroImage: Clinical</i> , 2022, 34, 102954.	1.4	3
7	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
8	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. <i>NeuroImage: Clinical</i> , 2022, 34, 102999.	1.4	11
9	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. <i>Neurology</i> , 2022, 98, .	1.5	10
10	Posterior cortical atrophy: Primary occipital variant. <i>European Journal of Neurology</i> , 2022, 29, 2138-2143.	1.7	7
11	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. <i>Brain Sciences</i> , 2022, 12, 378.	1.1	1
12	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 212-217.	0.8	8
13	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2022, 37, 702-712.	2.2	14
14	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.5	12
15	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. <i>Brain Communications</i> , 2022, 4, .	1.5	5
16	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 193-202.	0.7	1
17	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. <i>NeuroImage: Clinical</i> , 2022, 35, 103030.	1.4	8
18	Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2022, 101, 9-14.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 1693-1706.	1.6	44
20	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. <i>Annals of Neurology</i> , 2021, 89, 520-533.	2.8	21
21	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 17-28.	0.7	5
22	Phonological Errors in Posterior Cortical Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 2021, 50, 195-203.	0.7	8
23	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. <i>Journal of Speech, Language, and Hearing Research</i> , 2021, 64, 392-404.	0.7	7
24	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , 2021, 27, 212-222.	0.2	4
25	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. <i>Journal of Neurology</i> , 2021, 268, 3409-3420.	1.8	12
26	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 683-693.	1.2	7
27	Update on neuroimaging in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021, 34, 525-531.	1.8	4
28	Old age genetically confirmed frontotemporal lobar degeneration with TDP43 has limbic predominant TDP43 deposition. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1050-1059.	1.8	10
29	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. <i>Journal of Neurology</i> , 2021, 268, 4752-4758.	1.8	5
30	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. <i>Neurology</i> , 2021, 97, e523-e534.	1.5	4
31	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. <i>Nature Communications</i> , 2021, 12, 3452.	5.8	34
32	Neurodegeneration of the visual word form area in a patient with word form alexia. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 359-360.	0.2	5
33	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. <i>American Journal of Speech-Language Pathology</i> , 2021, 30, 1361-1372.	0.9	12
34	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2669-2675.	2.2	4
35	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. <i>Nature Reviews Neurology</i> , 2021, 17, 601-620.	4.9	41
36	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. <i>Brain Communications</i> , 2021, 3, fcab182.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. <i>Neurology</i> , 2021, 97, 908-909.	1.5	7
38	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24
39	Laboratory based assessment of gait and balance impairment in patients with progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118054.	0.3	4
40	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 9-12.	1.1	4
41	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. <i>Neurobiology of Aging</i> , 2021, 108, 90-98.	1.5	11
42	In vivo imaging and autoradiography in a case of autopsy-confirmed Pick disease. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000000755.	0.8	4
43	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. <i>Neurology: Clinical Practice</i> , 2021, 11, 249-255.	0.8	9
44	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2021, 32, 102850.	1.4	13
45	Dynamic Aphasia as a Variant of Frontotemporal Dementia. <i>Cognitive and Behavioral Neurology</i> , 2021, 34, 303-318.	0.5	2
46	Relationship of APOE, age, amyloid and clinical phenotype in Alzheimer disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
47	Heterogeneity in imaging-based spread of tau and atrophy in atypical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
48	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
49	Dysphagia in Progressive Supranuclear Palsy. <i>Dysphagia</i> , 2020, 35, 667-676.	1.0	25
50	Longitudinal flortaucipir ([¹⁸ F]AV-1451) PET imaging in primary progressive apraxia of speech. <i>Cortex</i> , 2020, 124, 33-43.	1.1	5
51	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 34-40.	1.1	20
52	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
53	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. <i>Neurocase</i> , 2020, 26, 259-263.	0.2	6
54	Longitudinal Amyloid- β^2 PET in Atypical Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 377-389.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 927-937.	1.2	14
56	Sensitivity and Specificity of Tau and Amyloid β^2 Positron Emission Tomography in Frontotemporal Lobar Degeneration. <i>Annals of Neurology</i> , 2020, 88, 1009-1022.	2.8	32
57	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. <i>Brain</i> , 2020, 143, 3463-3476.	3.7	45
58	loflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> , 2020, 267, 2603-2611.	1.8	12
59	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. <i>Neurology</i> , 2020, 95, e23-e34.	1.5	27
60	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
61	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. <i>Neurobiology of Aging</i> , 2020, 92, 135-140.	1.5	3
62	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. <i>NeuroImage: Clinical</i> , 2020, 25, 102152.	1.4	46
63	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14
64	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
65	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
66	Neuroanatomical correlates of phonologic errors in logopenic progressive aphasia. <i>Brain and Language</i> , 2020, 204, 104773.	0.8	15
67	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. <i>Neurobiology of Aging</i> , 2020, 92, 92-97.	1.5	13
68	Western Aphasia Battery - Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 498-510.	0.9	24
69	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. <i>American Journal of Speech-Language Pathology</i> , 2020, 29, 1976-1986.	0.9	13
70	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. <i>Neurology</i> , 2020, 95, e3190-e3202.	1.5	13
71	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 1618-1631.	1.9	53
72	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. <i>Brain and Language</i> , 2019, 197, 104676.	0.8	29

#	ARTICLE	IF	CITATIONS
91	The influence of β -amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. <i>Neurology</i> , 2019, 92, e710-e722.	1.5	10
92	Electroencephalography in primary progressive aphasia and apraxia of speech. <i>Aphasiology</i> , 2019, 33, 1410-1417.	1.4	9
93	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1713-1724.	1.2	45
94	[¹⁸ F]AV-1451 tau-PET and primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 83, 599-611.	2.8	73
95	Multimodal neuroimaging provides insights into the biology of Alzheimer's disease. <i>Brain</i> , 2018, 141, 326-329.	3.7	3
96	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
97	Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 3-9.	1.1	27
98	[¹⁸ F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. <i>Annals of Neurology</i> , 2018, 83, 248-257.	2.8	67
99	Longitudinal structural and molecular neuroimaging in agrammatic primary progressive aphasia. <i>Brain</i> , 2018, 141, 302-317.	3.7	42
100	Tau Imaging in Parkinsonism: What Have We Learned So Far?. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 118-130.	0.8	14
101	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
102	Disrupted functional connectivity in primary progressive apraxia of speech. <i>NeuroImage: Clinical</i> , 2018, 18, 617-629.	1.4	36
103	Molecular neuroimaging in primary progressive aphasia with predominant agraphia. <i>Neurocase</i> , 2018, 24, 121-123.	0.2	2
104	ICP-083: DIAGNOSTIC UTILITY OF [18F]AV-1451 PET, FDG-PET AND MRI TO DIFFERENTIATE THE THREE VARIANTS OF PRIMARY PROGRESSIVE APHASIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P71.	0.4	0
105	IC-0205: THE INFLUENCE OF AGE ON REGIONAL [¹⁸ F]AV-1451 PET, PITTSBURGH COMPOUND B PET AND MRI ATROPHY IN ATYPICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P6.	0.4	0
106	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. <i>Journal of the Acoustical Society of America</i> , 2018, 144, 3364-3370.	0.5	5
107	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2018, 27, 1303-1318.	0.9	36
108	Association of Apolipoprotein E ϵ 4 With Transactive Response DNA-Binding Protein 43. <i>JAMA Neurology</i> , 2018, 75, 1347.	4.5	60

#	ARTICLE	IF	CITATIONS
109	Patterns of Neuropsychological Dysfunction and Cortical Volume Changes in Logopenic Aphasia. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1015-1025.	1.2	26
110	Quantitative assessment of grammar in amyloid-negative logopenic aphasia. <i>Brain and Language</i> , 2018, 186, 26-31.	0.8	7
111	Alzheimer's disease neuroimaging. <i>Current Opinion in Neurology</i> , 2018, 31, 396-404.	1.8	24
112	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	0.8	106
113	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
114	Non-right handed primary progressive apraxia of speech. <i>Journal of the Neurological Sciences</i> , 2018, 390, 246-254.	0.3	4
115	Quantitative Analysis of Agrammatism in Agrammatic Primary Progressive Aphasia and Dominant Apraxia of Speech. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 2337-2346.	0.7	19
116	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. <i>Neurocase</i> , 2018, 24, 111-120.	0.2	25
117	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
118	Temporal acoustic measures distinguish primary progressive apraxia of speech from primary progressive aphasia. <i>Brain and Language</i> , 2017, 168, 84-94.	0.8	56
119	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
120	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	2.2	179
121	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
122	Brain tau deposition linked to systemic causes of death in normal elderly. <i>Neurobiology of Aging</i> , 2017, 50, 163-166.	1.5	2
123	Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech. <i>Neurology</i> , 2017, 89, 2271-2279.	1.5	30
124	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
125	Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. <i>Lancet Neurology</i> , The, 2017, 16, 917-924.	4.9	159
126	[¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 124-133.	2.2	136

#	ARTICLE	IF	CITATIONS
127	¹⁸ F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 632-638.	2.8	91
128	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. <i>Cortex</i> , 2017, 90, 138-148.	1.1	22
129	[ICâ€Pâ€204]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P149.	0.4	0
130	[O1â€06â€05]: SUBJECTâ€LEVEL ASSESSMENT OF REGIONAL CORRELATIONS BETWEEN TAUâ€PET, AMYLOIDâ€PET, MRI AND FDGâ€PET ACROSS THE CLINICAL SPECTRUM OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P203.	0.4	0
131	ICâ€Pâ€201: Predicting Amyloid Deposition in Progressive Aphasia and Apraxia of Speech Using Clinical and Mri Data. <i>Alzheimer's and Dementia</i> , 2016, 12, P144.	0.4	0
132	ICâ€Pâ€203: AVâ€1451 TAUâ€PET Binding in Typical and Atypical Syndromic Variants of Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P145.	0.4	0
133	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1019-1029.	1.2	24
134	[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. <i>Acta Neuropathologica</i> , 2016, 132, 931-933.	3.9	116
135	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 29-35.	1.1	18
136	Coprophagia in neurologic disorders. <i>Journal of Neurology</i> , 2016, 263, 1008-1014.	1.8	18
137	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. <i>Acta Neuropathologica</i> , 2016, 131, 571-585.	3.9	244
138	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. <i>NeuroImage: Clinical</i> , 2016, 11, 90-98.	1.4	10
139	Uncovering Neuroanatomical Networks Responsible for Abnormal Eating Behavior in Frontotemporal Dementia. <i>JAMA Neurology</i> , 2016, 73, 267.	4.5	1
140	Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. <i>Neurocase</i> , 2016, 22, 55-59.	0.2	11
141	Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 429-435.	1.2	78
142	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	1.2	27
143	TAR DNAâ€binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. <i>Annals of Neurology</i> , 2015, 78, 697-709.	2.8	96
144	Dominant Frontotemporal Dementia Mutations in 140 Cases of Primary Progressive Aphasia and Speech Apraxia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 281-286.	0.7	32

#	ARTICLE	IF	CITATIONS
145	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. <i>Brain and Language</i> , 2015, 142, 45-53.	0.8	49
146	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	1.2	19
147	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2015, 36, 1245-1252.	1.5	83
148	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	1.1	133
149	Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. <i>Journal of Neurology</i> , 2015, 262, 2064-2072.	1.8	10
150	Primary Progressive Apraxia of Speech: Clinical Features and Acoustic and Neurologic Correlates. <i>American Journal of Speech-Language Pathology</i> , 2015, 24, 88-100.	0.9	69
151	Neuropsychiatric Symptoms in Primary Progressive Aphasia and Apraxia of Speech. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 228-238.	0.7	38
152	Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. <i>Journal of Neurology</i> , 2015, 262, 1483-1492.	1.8	53
153	Quantitative application of the primary progressive aphasia consensus criteria. <i>Neurology</i> , 2014, 82, 1119-1126.	1.5	147
154	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. <i>Neurology</i> , 2014, 82, 1729-1735.	1.5	63
155	Progranulin-associated PiB-negative logopenic primary progressive aphasia. <i>Journal of Neurology</i> , 2014, 261, 604-614.	1.8	69
156	Progressive Apraxia of Speech and Primary Progressive Aphasias. , 2014, , 213-230.		1
157	The pimple sign of progressive supranuclear palsy syndrome. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 180-185.	1.1	32
158	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.4	14
159	Staging TDP-43 pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 441-450.	3.9	278
160	<i>APOE</i> ϵ 4 influences β -amyloid deposition in primary progressive aphasia and speech apraxia. <i>Alzheimer's and Dementia</i> , 2014, 10, 630-636.	0.4	31
161	The evolution of primary progressive apraxia of speech. <i>Brain</i> , 2014, 137, 2783-2795.	3.7	134
162	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. <i>Journal of Neurology</i> , 2014, 261, 710-716.	1.8	60

#	ARTICLE	IF	CITATIONS
163	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 811-824.	3.9	336
164	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	2.1	155
165	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 493-498.	1.1	49
166	Ideomotor apraxia in agrammatic and logopenic variants of primary progressive aphasia. <i>Journal of Neurology</i> , 2013, 260, 1594-1600.	1.8	21
167	Identification of an atypical variant of logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 139-144.	0.8	49
168	Modeling trajectories of regional volume loss in progressive supranuclear palsy. <i>Movement Disorders</i> , 2013, 28, 1117-1124.	2.2	36
169	Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. <i>Neurobiology of Aging</i> , 2013, 34, 636-639.	1.5	54
170	Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects?. <i>NeuroImage: Clinical</i> , 2013, 2, 249-257.	1.4	44
171	Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia. <i>Brain and Language</i> , 2013, 127, 127-134.	0.8	53
172	Aphasia with left occipitotemporal hypometabolism: A novel presentation of posterior cortical atrophy?. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 1237-1240.	0.8	12
173	Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: An MRI and FDG-PET study. <i>Brain and Language</i> , 2013, 125, 245-252.	0.8	66
174	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. <i>Brain</i> , 2013, 136, 455-470.	3.7	37
175	Elevated occipital β -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	0.9	28
176	Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA. <i>Neurology</i> , 2013, 81, 337-345.	1.5	142
177	Tauopathies. , 2013, , 147-166.		2
178	FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer's Type. <i>PLoS ONE</i> , 2013, 8, e62471.	1.1	100
179	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. <i>Brain</i> , 2012, 135, 794-806.	3.7	355
180	Comparison of Imaging Biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. <i>Archives of Neurology</i> , 2012, 69, 614.	4.9	60

#	ARTICLE	IF	CITATIONS
181	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	3.7	322
182	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. <i>Archives of Neurology</i> , 2012, 69, 1164-9.	4.9	17
183	Imaging brain atrophy in progressive supranuclear palsy and corticobasal syndromes: potential for diagnosis and monitoring of disease progression. <i>Neurodegenerative Disease Management</i> , 2012, 2, 589-598.	1.2	0
184	Recent Advances in the Imaging of Frontotemporal Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 715-723.	2.0	39
185	Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: Determining sample size for treatment trials. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 252-256.	1.1	49
186	Right temporal variant frontotemporal dementia with motor neuron disease. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 85-91.	0.8	20
187	Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. <i>Brain</i> , 2012, 135, 1522-1536.	3.7	325
188	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 868-877.	4.9	355
189	Neuroimaging in frontotemporal lobar degenerationâ€”predicting molecular pathology. <i>Nature Reviews Neurology</i> , 2012, 8, 131-142.	4.9	65
190	Primary lateral sclerosis as progressive supranuclear palsy: Diagnosis by diffusion tensor imaging. <i>Movement Disorders</i> , 2012, 27, 903-906.	2.2	11
191	Imaging measures predict progression in progressive supranuclear palsy. <i>Movement Disorders</i> , 2012, 27, 1801-1804.	2.2	19
192	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	2.1	90
193	Focal brain atrophy in gastric bypass patients with cognitive complaints. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1671-1676.	0.8	8
194	Disrupted thalamocortical connectivity in PSP: A resting-state fMRI, DTI, and VBM study. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 599-605.	1.1	146
195	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. <i>Neurobiology of Aging</i> , 2011, 32, 1531-1541.	1.5	105
196	Corticobasal degeneration: a pathologically distinct 4R tauopathy. <i>Nature Reviews Neurology</i> , 2011, 7, 263-272.	4.9	270
197	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 372-8.	1.1	61
198	Gray matter correlates of behavioral severity in progressive supranuclear palsy. <i>Movement Disorders</i> , 2011, 26, 493-498.	2.2	43

#	ARTICLE	IF	CITATIONS
199	Predicting functional decline in behavioural variant frontotemporal dementia. <i>Brain</i> , 2011, 134, 432-448.	3.7	45
200	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 196-203.	0.9	170
201	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2011, 68, 753-60.	4.9	110
202	Assessing Subtle Structural Changes in Alzheimer's Disease Patients. <i>Methods in Molecular Biology</i> , 2011, 711, 535-550.	0.4	2
203	Progression of Atrophy in Alzheimer's Disease and Related Disorders. <i>Neurotoxicity Research</i> , 2010, 18, 339-346.	1.3	66
204	Anatomical differences between CBS corticobasal degeneration and CBS Alzheimer's disease. <i>Movement Disorders</i> , 2010, 25, 1246-1252.	2.2	71
205	Fluorodeoxyglucose F18 Positron Emission Tomography in Progressive Apraxia of Speech and Primary Progressive Aphasia Variants. <i>Archives of Neurology</i> , 2010, 67, 596-605.	4.9	93
206	Symmetric corticobasal degeneration (S-CBD). <i>Parkinsonism and Related Disorders</i> , 2010, 16, 208-214.	1.1	56
207	The protective role of brain size in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1799-1801.	1.4	11
208	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. <i>Neurodegenerative Diseases</i> , 2009, 6, 106-117.	0.8	47
209	The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009, 132, 1287-1298.	3.7	277
210	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. <i>Brain</i> , 2009, 132, 2932-2946.	3.7	277
211	Voxel-Based Morphometry: An Automated Technique for Assessing Structural Changes in the Brain. <i>Journal of Neuroscience</i> , 2009, 29, 9661-9664.	1.7	279
212	Volumetric MRI and cognitive measures in Alzheimer disease. <i>Journal of Neurology</i> , 2008, 255, 567-574.	1.8	121
213	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 685-691.	1.9	2,553
214	β-amyloid burden is not associated with rates of brain atrophy. <i>Annals of Neurology</i> , 2008, 63, 204-212.	2.8	187
215	Voxel-based morphometry in autopsy proven PSP and CBD. <i>Neurobiology of Aging</i> , 2008, 29, 280-289.	1.5	221
216	Anatomic correlates of stereotypies in frontotemporal lobar degeneration. <i>Neurobiology of Aging</i> , 2008, 29, 1859-1863.	1.5	40

#	ARTICLE	IF	CITATIONS
217	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. <i>NeuroImage</i> , 2008, 39, 1186-1197.	2.1	391
218	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. <i>NeuroImage</i> , 2008, 39, 1034-1040.	2.1	52
219	Antemortem MRI based STructural Abnormality INdex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. <i>NeuroImage</i> , 2008, 42, 559-567.	2.1	152
220	Longitudinal imaging: change and causality. <i>Current Opinion in Neurology</i> , 2008, 21, 410-416.	1.8	13
221	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1130.	4.9	185
222	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. <i>Archives of Neurology</i> , 2007, 64, 371.	4.9	82
223	NEUROIMAGING IN DEMENTIA. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2007, 13, 180-203.	0.4	1
224	Imaging correlates of posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2007, 28, 1051-1061.	1.5	176
225	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. <i>NeuroImage</i> , 2007, 35, 207-213.	2.1	122
226	Voxel-based morphometry and its application to movement disorders. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S406-S416.	1.1	30
227	Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. <i>Brain</i> , 2007, 130, 708-719.	3.7	286
228	3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. <i>Brain</i> , 2007, 130, 1777-1786.	3.7	541
229	Neuroimaging in Dementia. <i>Neurologic Clinics</i> , 2007, 25, 843-857.	0.8	20
230	Neuroimaging in Dementia. <i>PET Clinics</i> , 2007, 2, 15-24.	1.5	2
231	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. <i>Brain</i> , 2006, 129, 1385-1398.	3.7	624
232	Visual Hallucinations in Posterior Cortical Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1427.	4.9	70
233	Frontotemporal Lobar Degeneration Without Lobar Atrophy. <i>Archives of Neurology</i> , 2006, 63, 1632.	4.9	52
234	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. <i>Annals of Neurology</i> , 2006, 59, 200-203.	2.8	30

#	ARTICLE	IF	CITATIONS
235	Measurements of the Amygdala and Hippocampus in Pathologically Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Archives of Neurology, 2006, 63, 1434.	4.9	139
236	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146
237	Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration. Neurology, 2006, 66, 102-104.	1.5	351
238	Comparisons Between Alzheimer Disease, Frontotemporal Lobar Degeneration, and Normal Aging With Brain Mapping. Topics in Magnetic Resonance Imaging, 2005, 16, 409-425.	0.7	71
239	A Volumetric Magnetic Resonance Imaging Study of the Amygdala in Frontotemporal Lobar Degeneration and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 238-244.	0.7	43
240	Magnetic Resonance Imaging Signatures of Tissue Pathology in Frontotemporal Dementia. Archives of Neurology, 2005, 62, 1402.	4.9	132
241	Longitudinal Patterns of Regional Change on Volumetric MRI in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2004, 17, 307-310.	0.7	70
242	Voxel-Based Morphometry in Tau-Positive and Tau-Negative Frontotemporal Lobar Degenerations. Neurodegenerative Diseases, 2004, 1, 225-230.	0.8	21
243	Using nine degrees-of-freedom registration to correct for changes in voxel size in serial MRI studies. Magnetic Resonance Imaging, 2004, 22, 993-999.	1.0	14
244	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet, The, 2003, 362, 1121-1122.	6.3	190
245	A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging. Archives of Neurology, 2003, 60, 989.	4.9	736
246	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Annals of Neurology, 2001, 49, 433-442.	2.8	641